126
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Amoroso A, An Q, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Bennett JV, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Cheng W, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RB, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Du SX, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Fu Y, Gao XL, Gao Y, Gao Y, Gao YG, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guo YP, Guskov A, Han S, Han TT, Han TZ, Hao XQ, Harris FA, He KL, Heinsius FH, Held T, Heng YK, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang Z, Huesken N, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Jiang HB, Jiang XS, Jiang XY, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavezzi L, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li HB, Li HJ, Li JL, Li JQ, Li K, Li LK, Li L, Li PL, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li ZB, Li ZY, Liang H, Liang H, Liang YF, Liang YT, Liao LZ, Libby J, Lin CX, Liu B, Liu BJ, Liu CX, Liu D, Liu DY, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LY, Liu Q, Liu SB, Liu T, Liu X, Liu YB, Liu ZA, Liu ZQ, Long YF, Lou XC, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XN, Ma XX, Ma XY, Ma YM, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Mo YJ, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan Y, Papenbrock M, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Pitka A, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sarantsev A, Savrié M, Schelhaas Y, Schnier C, Schoenning K, Shan W, Shan XY, Shao M, Shen CP, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song QQ, Song YX, Sosio S, Spataro S, Sui FF, Sun GX, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Thoren V, Tsednee B, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang Y, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZY, Wang Z, Wang Z, Weber T, Wei DH, Weidenkaff P, Weidner F, Wen HW, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao YJ, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xiong XA, Xu GF, Xu JJ, Xu QJ, Xu W, Xu XP, Yan L, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang RX, Yang SL, Yang YH, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan W, Yuan XQ, Yuan Y, Yue CX, Yuncu A, Zafar AA, Zeng Y, Zhang BX, Zhang G, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang L, Zhang L, Zhang S, Zhang SF, Zhang TJ, Zhang XY, Zhang Y, Zhang YH, Zhang YT, Zhang Y, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng Y, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu WJ, Zhu XL, Zhu YC, Zhu ZA, Zou BS, Zou JH. Direct Measurement of the Branching Fractions B(ψ(3686)→J/ψX) and B(ψ(3770)→J/ψX), and Observation of the State R(3760) in e^{+}e^{-}→J/ψX. PHYSICAL REVIEW LETTERS 2021; 127:082002. [PMID: 34477419 DOI: 10.1103/physrevlett.127.082002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 06/21/2021] [Accepted: 07/13/2021] [Indexed: 06/13/2023]
Abstract
We report a measurement of the observed cross sections of e^{+}e^{-}→J/ψX based on 3.21 fb^{-1} of data accumulated at energies from 3.645 to 3.891 GeV with the BESIII detector operated at the BEPCII collider. In analysis of the cross sections, we measured the decay branching fractions of B(ψ(3686)→J/ψX)=(64.4±0.6±1.6)% and B(ψ(3770)→J/ψX)=(0.5±0.2±0.1)% for the first time. The energy-dependent line shape of these cross sections cannot be well described by two Breit-Wigner (BW) amplitudes of the expected decays ψ(3686)→J/ψX and ψ(3770)→J/ψX. Instead, it can be better described with one more BW amplitude of the decay R(3760)→J/ψX. Under this assumption, we extracted the R(3760) mass M_{R(3760)}=3766.2±3.8±0.4 MeV/c^{2} , total width Γ_{R(3760)}^{tot}=22.2±5.9±1.4 MeV, and product of leptonic width and decay branching fraction Γ_{R(3760)}^{ee}B[R(3760)→J/ψX]=(79.4±85.5±11.7) eV. The significance of the R(3760) is 5.3σ. The first uncertainties of these measured quantities are from fits to the cross sections and second systematic.
Collapse
|
127
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu S, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, He K, Heinsius F, Heinz C, Held T, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Hüsken N, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Lin C, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu S, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Poling R, Prasad V, Qi H, Qi H, Qi K, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan D, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan X, Yuan Y, Yuan Z, Yue C, Zafar A, Zeng XZ, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Measurement of the branching fraction of leptonic decay
Ds+→τ+ντ
via
τ+→π+π0ν¯τ. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.032001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
128
|
Vondracek P, Panek R, Hron M, Havlicek J, Weinzettl V, Todd T, Tskhakaya D, Cunningham G, Hacek P, Hromadka J, Junek P, Krbec J, Patel N, Sestak D, Varju J, Adamek J, Balazsova M, Balner V, Barton P, Bielecki J, Bilkova P, Błocki J, Bocian D, Bogar K, Bogar O, Boocz P, Borodkina I, Brooks A, Bohm P, Burant J, Casolari A, Cavalier J, Chappuis P, Dejarnac R, Dimitrova M, Dudak M, Duran I, Ellis R, Entler S, Fang J, Farnik M, Ficker O, Fridrich D, Fukova S, Gerardin J, Hanak I, Havranek A, Herrmann A, Horacek J, Hronova O, Imrisek M, Isernia N, Jaulmes F, Jerab M, Kindl V, Komm M, Kovarik K, Kral M, Kripner L, Macusova E, Majer T, Markovic T, Matveeva E, Mikszuta-Michalik K, Mohelnik M, Mysiura I, Naydenkova D, Nemec I, Ortwein R, Patocka K, Peterka M, Podolnik A, Prochazka F, Prevratil J, Reboun J, Scalera V, Scholz M, Svoboda J, Swierblewski J, Sos M, Tadros M, Titus P, Tomes M, Torres A, Tracz G, Turjanica P, Varavin M, Veselovsky V, Villone F, Wąchal P, Yanovskiy V, Zadvitskiy G, Zajac J, Zak A, Zaloga D, Zelda J, Zhang H. Preliminary design of the COMPASS upgrade tokamak. FUSION ENGINEERING AND DESIGN 2021. [DOI: 10.1016/j.fusengdes.2021.112490] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
129
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Amoroso A, An Q, Anita, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Bennett J, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai J, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Du S, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Fritsch M, Fu C, Fu Y, Gao X, Gao Y, Gao Y, Gao Y, Garzia I, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu S, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guo Y, Guskov A, Han S, Han T, Han T, Hao X, Harris F, He K, Heinsius F, Held T, Heng Y, Himmelreich M, Holtmann T, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Z, Huesken N, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Jiang H, Jiang X, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavezzi L, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li J, Li J, Li K, Li L, Li L, Li P, Li P, Li S, Li W, Li W, Li X, Li X, Li Z, Li Z, Liang H, Liang H, Liang Y, Liang Y, Liao L, Libby J, Lin C, Liu B, Liu B, Liu C, Liu D, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu K, Liu K, Liu K, Liu L, Liu Q, Liu S, Liu S, Liu T, Liu X, Liu Y, Liu Z, Liu Z, Long Y, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lusso S, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Ma X, Ma Y, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Pitka A, Poling R, Prasad V, Qi H, Qi H, Qi M, Qi T, Qian S, Qian WB, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Shan D, Shan W, Shan X, Shao M, Shen C, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song Q, Song W, Song Y, Sosio S, Spataro S, Sui F, Sun G, Sun J, Sun L, Sun S, Sun T, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Thoren V, Tsednee B, Uman I, Wang B, Wang B, Wang C, Wang D, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidenkaff P, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Y, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xiong X, Xu G, Xu J, Xu Q, Xu W, Xu X, Yan L, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang R, Yang S, Yang Y, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan W, Yuan X, Yuan Y, Yuan Z, Yue C, Yuncu A, Zafar A, Zeng Y, Zhang B, Zhang G, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang S, Zhang S, Zhang T, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu W, Zhu X, Zhu Y, Zhu Z, Zou B, Zou J. Amplitude analysis and branching fraction measurement of
Ds+→K+K−π+. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.012016] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
130
|
Lin C, Fang J, Xiang Q, Zhou R, Yang L. [Exendin-4 promotes autophagy to relieve lipid deposition in a NAFLD cell model by activating AKT/mTOR signaling pathway]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2021; 41:1073-1078. [PMID: 34308859 DOI: 10.12122/j.issn.1673-4254.2021.07.16] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the effect of exendin-4 on lipid deposition in hepatocytes and explore its possible mechanism for treatment of nonalcoholic fatty liver disease (NAFLD). METHODS Human normal hepatocyte line LO2 and hepatoma cell line HepG2 were treated with palmitic acid (PA) to mimic hepatocyte steatosis or with combined treatments with PA+exendin-4 or PA+exendin-4+3BDO. Lipid deposition and proliferation of the two cell lines following treatment with PA or PA+exendin-4 were detected using Oil Red O staining and CCK8 assay, and the expression of p-mTOR, m-TOR, p-AKT, AKT and autophagy-related proteins LC3-Ⅰ/Ⅱ and p62 were detected with Western blotting; the expression of GLP-1R was detected with both Western blotting and immunofluorescence assay. The expression of LC3-Ⅰ/Ⅱ and p62 in the cells following treatment with PA+exendin-4 and PA+exendin-4+3BDO was detected with Western blotting. RESULTS Lipid deposition in the two cell lines increased significantly after PA treatment, but was alleviated by co-treatment with exendin-4. PA treatment significantly inhibited the proliferation of the two cell lines (P < 0.01), and this inhibitory effect was obviously attenuated by exendin-4 (P < 0.05). Immunofluorescence assay showed that both LO2 and HepG2 cells expressed GLP-1R. The expression of p-mTOR was significantly lower and that of p-AKT was higher in cells treated with PA+exendin-4 than in PA-treated cells. Exendin-4 also down-regulated the autophagy-associated protein p62 and up-regulated the expression of LC3-Ⅱ in PA-treated cells, and this effect was obviously reversed by 3BDO. CONCLUSION Exendin-4 may activate the AKT-mTOR signal pathway to promote autophagy via its direct action on GLP-1R. Exendin-4 can also alleviate lipid deposition and promote proliferation of PA-treated hepatocytes, suggesting its important role in PA-induced lipid deposition in hepatocytes.
Collapse
|
131
|
Fang J, Wang S, Zhou J, Shao X, Sun H, Liang Y, He X, Jiang Y, Liu B, Jin X, Fang J, Du J. Electroacupuncture Regulates Pain Transition Through Inhibiting PKCε and TRPV1 Expression in Dorsal Root Ganglion. Front Neurosci 2021; 15:685715. [PMID: 34354561 PMCID: PMC8329384 DOI: 10.3389/fnins.2021.685715] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 05/28/2021] [Indexed: 11/16/2022] Open
Abstract
Many cases of acute pain can be resolved with few side effects. However, some cases of acute pain may persist beyond the time required for tissue injury recovery and transit to chronic pain, which is hard to treat. The mechanisms underlying pain transition are not entirely understood, and treatment strategies are lacking. In this study, the hyperalgesic priming model was established on rats to study pain transition by injection of carrageenan (Car) and prostaglandin E2 (PGE2). The expression levels of protein kinase C epsilon (PKCε) and transient receptor potential vanilloid 1 (TRPV1) in the L4–L6 dorsal root ganglion (DRG) were investigated. Electroacupuncture (EA) is a form of acupuncture in which a small electric current is passed between a pair of acupuncture needles. EA was administrated, and its effect on hyperalgesia and PKCε and TRPV1 expression was investigated. The PKCε–TRPV1 signaling pathway in DRG was implicated in the pain transition. EA increased the pain threshold of model animals and regulated the high expression of PKCε and TRPV1. Moreover, EA also regulated hyperalgesia and high TRPV1 expression induced by selective PKCε activation. We also found that EA partly increased chronic pain threshold, even though it was only administered between the Car and PGE2 injections. These findings suggested that EA could prevent the transition from acute to chronic pain by inhibiting the PKCε and TRPV1 expression in the peripheral nervous system.
Collapse
|
132
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu S, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, Hüsken N, He K, Heinsius F, Heinz C, Held T, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Lin C, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu S, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Poling R, Prasad V, Qi H, Qi H, Qi K, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan D, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan X, Yuan Y, Yuan Z, Yue C, Yuncu A, Zafar A, Zeng X, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Study of the decay
D+→K*(892)+KS0
in
D+→K+KS0π0. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.012006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
133
|
Zhou J, Ma R, Jin Y, Fang J, Du J, Shao X, Liang Y, Fang J. Molecular mechanisms of opioid tolerance: From opioid receptors to inflammatory mediators (Review). Exp Ther Med 2021; 22:1004. [PMID: 34345286 PMCID: PMC8311239 DOI: 10.3892/etm.2021.10437] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 04/19/2021] [Indexed: 12/14/2022] Open
Abstract
Opioids are considered the most effective analgesics for the treatment of both acute and chronic pain. However, prolonged opioid use can induce a certain level of tolerance to its analgesic effects, leading to a reduction in its effectiveness, addiction and abuse. A better understanding of the mechanisms underlying opioid tolerance may provide insights into this phenomenon and aid in the development of novel methods to combat the side effects of opioid tolerance. The present review focused on two major contributors to tolerance, opioid receptors and inflammatory mediators. The molecular mechanisms involved in the desensitization of the opioid receptors were briefly described, including their phosphorylation, internalisation and recycling. Subsequently, the effects of Toll like receptor 4/NOD-like receptor family pyrin domain containing 3-mediated proinflammatory responses in opioid tolerance were discussed, aiming in supporting the identification of novel therapeutic targets.
Collapse
|
134
|
Luo YH, Zhang L, Wang MY, Fang J, Xia JY, Yu XL. Anti-cancer effects of baicalein on cervical carcinoma cells through down-regulation of the ERK/p38/MAPK pathway. J BIOL REG HOMEOS AG 2021; 35:945-952. [PMID: 34060266 DOI: 10.23812/21-52-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The objective of this study was to investigate the effects of baicalein on apoptosis of HeLa human cervical cancer (CC) cells and to elucidate the underlying mechanism. HeLa cells were treated with 20, 50, 100, or 200 μmol/L baicalein for 24, 36, and 48 hours, and CCK-8 assays were used to detect cell viability, and flow cytometry was performed to assess apoptosis rate. Reverse-transcription quantitative PCR was used to measure ERK1/2, p38, and JNK mRNA levels in HeLa cells, and western blotting was performed to measure ERK1/2, p38, and JNK protein levels. The CCK-8 assay showed that the OD value of HeLa cells gradually decreased with increasing baicalein concentrations (P < 0.01) and treatment time (P < 0.01). These results indicated a negative time- and dose-dependent effect of baicalein on HeLa cells. Baicalein treatment of HeLa cells significantly increased apoptosis rate (P < 0.01). In HeLa cells treated with 50 or 200 μmol/L baicalein for 24 h, expression levels of ERK1/2 and p38 mRNA were significantly reduced, whereas that of JNK mRNA was increased (P < 0.01). The levels of phosphorylated ERK1/2 and p38 were significantly reduced, and the level of JNK protein was increased (P < 0.01). Taken together, baicalein appeared to exert anti-cancer effects on HeLa cells through induction of apoptosis and regulation of the ERK/p38/mitogen-activated protein kinase pathway.
Collapse
|
135
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, He K, Heinsius F, Heinz C, Held T, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Hüsken N, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Lin C, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu S, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Pogodin S, Poling R, Prasad V, Qi H, Qi H, Qi K, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan D, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan X, Yuan Y, Yuan Z, Yue C, Zafar A, Zeng XZ, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Measurement of the absolute branching fraction of inclusive semielectronic
Ds+
decays. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.012003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
136
|
Cao Z, Aharonian F, An Q, Bai LX, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Cai H, Cai JT, Cao Z, Chang J, Chang JF, Chen BM, Chen ES, Chen J, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen SH, Chen SZ, Chen TL, Chen XL, Chen Y, Cheng N, Cheng YD, Cui SW, Cui XH, Cui YD, D'Ettorre Piazzoli B, Dai BZ, Dai HL, Dai ZG, Della Volpe D, Dong XJ, Duan KK, Fan JH, Fan YZ, Fan ZX, Fang J, Fang K, Feng CF, Feng L, Feng SH, Feng YL, Gao B, Gao CD, Gao LQ, Gao Q, Gao W, Ge MM, Geng LS, Gong GH, Gou QB, Gu MH, Guo FL, Guo JG, Guo XL, Guo YQ, Guo YY, Han YA, He HH, He HN, He JC, He SL, He XB, He Y, Heller M, Hor YK, Hou C, Hou X, Hu HB, Hu S, Hu SC, Hu XJ, Huang DH, Huang QL, Huang WH, Huang XT, Huang XY, Huang ZC, Ji F, Ji XL, Jia HY, Jiang K, Jiang ZJ, Jin C, Ke T, Kuleshov D, Levochkin K, Li BB, Li C, Li C, Li F, Li HB, Li HC, Li HY, Li J, Li J, Li K, Li WL, Li XR, Li X, Li X, Li Y, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu H, Liu HD, Liu J, Liu JL, Liu JS, Liu JY, Liu MY, Liu RY, Liu SM, Liu W, Liu Y, Liu YN, Liu ZX, Long WJ, Lu R, Lv HK, Ma BQ, Ma LL, Ma XH, Mao JR, Masood A, Min Z, Mitthumsiri W, Montaruli T, Nan YC, Pang BY, Pattarakijwanich P, Pei ZY, Qi MY, Qi YQ, Qiao BQ, Qin JJ, Ruffolo D, Rulev V, Saiz A, Shao L, Shchegolev O, Sheng XD, Shi JY, Song HC, Stenkin YV, Stepanov V, Su Y, Sun QN, Sun XN, Sun ZB, Tam PHT, Tang ZB, Tian WW, Wang BD, Wang C, Wang H, Wang HG, Wang JC, Wang JS, Wang LP, Wang LY, Wang RN, Wang W, Wang W, Wang XG, Wang XJ, Wang XY, Wang Y, Wang YD, Wang YJ, Wang YP, Wang ZH, Wang ZX, Wang Z, Wang Z, Wei DM, Wei JJ, Wei YJ, Wen T, Wu CY, Wu HR, Wu S, Wu WX, Wu XF, Xi SQ, Xia J, Xia JJ, Xiang GM, Xiao DX, Xiao G, Xiao HB, Xin GG, Xin YL, Xing Y, Xu DL, Xu RX, Xue L, Yan DH, Yan JZ, Yang CW, Yang FF, Yang JY, Yang LL, Yang MJ, Yang RZ, Yang SB, Yao YH, Yao ZG, Ye YM, Yin LQ, Yin N, You XH, You ZY, Yu YH, Yuan Q, Zeng HD, Zeng TX, Zeng W, Zeng ZK, Zha M, Zhai XX, Zhang BB, Zhang HM, Zhang HY, Zhang JL, Zhang JW, Zhang LX, Zhang L, Zhang L, Zhang PF, Zhang PP, Zhang R, Zhang SR, Zhang SS, Zhang X, Zhang XP, Zhang YF, Zhang YL, Zhang Y, Zhang Y, Zhao B, Zhao J, Zhao L, Zhao LZ, Zhao SP, Zheng F, Zheng Y, Zhou B, Zhou H, Zhou JN, Zhou P, Zhou R, Zhou XX, Zhu CG, Zhu FR, Zhu H, Zhu KJ, Zuo X. Peta-electron volt gamma-ray emission from the Crab Nebula. Science 2021; 373:425-430. [PMID: 34261813 DOI: 10.1126/science.abg5137] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 06/23/2021] [Indexed: 11/03/2022]
Abstract
The Crab Nebula is a bright source of gamma rays powered by the Crab Pulsar's rotational energy through the formation and termination of a relativistic electron-positron wind. We report the detection of gamma rays from this source with energies from 5 × 10-4 to 1.1 peta-electron volts with a spectrum showing gradual steepening over three energy decades. The ultrahigh-energy photons imply the presence of a peta-electron volt electron accelerator (a pevatron) in the nebula, with an acceleration rate exceeding 15% of the theoretical limit. We constrain the pevatron's size between 0.025 and 0.1 parsecs and the magnetic field to ≈110 microgauss. The production rate of peta-electron volt electrons, 2.5 × 1036 ergs per second, constitutes 0.5% of the pulsar spin-down luminosity, although we cannot exclude a contribution of peta-electron volt protons to the production of the highest-energy gamma rays.
Collapse
|
137
|
Shao F, Fang J, Qiu M, Wang S, Xi D, Shao X, He X, Fang J, Du J. Electroacupuncture Ameliorates Chronic Inflammatory Pain-Related Anxiety by Activating PV Interneurons in the Anterior Cingulate Cortex. Front Neurosci 2021; 15:691931. [PMID: 34290586 PMCID: PMC8287862 DOI: 10.3389/fnins.2021.691931] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 06/09/2021] [Indexed: 12/11/2022] Open
Abstract
Chronic inflammatory pain is a common clinical disease that tends to be associated with negative emotions such as anxiety and depression. The anterior cingulate cortex (ACC) is involved in pain and pain-related anxiety, and γ-aminobutyric acid (GABA)-ergic interneurons play an important role in chronic pain and anxiety. Electroacupuncture (EA) has good analgesic and antianxiety effect, but the underlying mechanisms have not yet been fully elucidated. In this study, we established a chronic inflammatory pain model and observed that this model induced anxiety-like behaviors and decreased the numbers of parvalbumin (PV) and somatostatin (SOM) positive cells. Activation of PV but not SOM interneurons by chemogenetic techniques alleviated anxiety-like behaviors and pain sensation. EA treatment improved pain sensation, anxiety-like behaviors and increased the number of PV- positive cells in the ACC, but did not affect on the number of SOM-positive cells in the ACC. Moreover, specific inhibition of PV interneurons by chemogenetic methods reversed the analgesic and antianxiety effects of EA. These results suggest that EA ameliorates chronic inflammatory pain and pain-related anxiety by upregulating PV but not SOM interneurons in the ACC.
Collapse
|
138
|
Fang J, Zhu JM, Dai HL, He LM, Kong L. MicroRNA-198 inhibits metastasis of thyroid cancer by targeting H3F3A. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 24:12232-12240. [PMID: 33336742 DOI: 10.26355/eurrev_202012_24015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE This study was designed to investigate the role of microRNA-198 in thyroid cancer (TCa) progression. PATIENTS AND METHODS Quantitative real-time polymerase chain reaction (qRT-PCR) was carried out to examine microRNA-198 and H3F3A levels in tumor tissue specimens and paracancerous ones collected from 50 patients with TCa, and the interplay between microRNA-198 or H3F3A and some clinical indicators or prognosis of TCa patients was analyzed as well. MicroRNA-198 and H3F3A overexpression models were constructed using lentivirus in TCa cell lines TPC-1 and BHP2-7, and the impacts of microRNA-198 on TCa cell functions were evaluated by using cell counting kit-8 (CCK-8), plate clone formation, and transwell assays. Finally, recovery investigations were conducted to explore the underlying mechanisms as well as the interaction between microRNA-198 and H3F3A. RESULTS QRT-PCR indicated that in tumor tissues of TCa patients, microRNA-198 showed a remarkably lower expression than in adjacent normal tissue samples. Compared with patients with high expression of microRNA-198, those with microRNA-198 low expression had more advanced tumor stage, larger tumor size, higher lymph node metastasis rate, and lower overall survival rate. Meanwhile, the results of research on H3F3A were just opposite to the above observations on microRNA-198. In in vitro cell experiments, overexpression of microRNA-198 significantly weakened the proliferation and migration ability of thyroid tumor cells. Besides, Luciferase reporter gene experiment revealed that H3F3A was a specific target gene for microRNA-198. Moreover, qRT-PCR indicated that H3F3A and microRNA-198 were negatively correlated in thyroid carcinoma tissues. In addition, compared with NC group, overexpression of H3F3A markedly enhanced the migration and proliferative capacity of TCa cells. Lastly, recovery experiment revealed a mutual regulation between microRNA-198 and H3F3A, the two of which may together participate in the malignant progression of TCa. CONCLUSIONS MicroRNA-198 is remarkably reduced in TCa and inhibits malignant progression of TCa by regulating H3F3A. Meanwhile, microRNA-198 is remarkably associated with pathological stage, tumor size, lymph node metastasis, and poor prognosis of TCa.
Collapse
|
139
|
Aharonian F, An Q, Bai LX, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Cai H, Cai JT, Cao Z, Cao Z, Chang J, Chang JF, Chang XC, Chen BM, Chen J, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen SH, Chen SZ, Chen TL, Chen XL, Chen Y, Cheng N, Cheng YD, Cui SW, Cui XH, Cui YD, Dai BZ, Dai HL, Dai ZG, Della Volpe D, D'Ettorre Piazzoli B, Dong XJ, Fan JH, Fan YZ, Fan ZX, Fang J, Fang K, Feng CF, Feng L, Feng SH, Feng YL, Gao B, Gao CD, Gao Q, Gao W, Ge MM, Geng LS, Gong GH, Gou QB, Gu MH, Guo JG, Guo XL, Guo YQ, Guo YY, Han YA, He HH, He HN, He JC, He SL, He XB, He Y, Heller M, Hor YK, Hou C, Hou X, Hu HB, Hu S, Hu SC, Hu XJ, Huang DH, Huang QL, Huang WH, Huang XT, Huang ZC, Ji F, Ji XL, Jia HY, Jiang K, Jiang ZJ, Jin C, Kuleshov D, Levochkin K, Li BB, Li C, Li C, Li F, Li HB, Li HC, Li HY, Li J, Li K, Li WL, Li X, Li X, Li XR, Li Y, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu H, Liu HD, Liu J, Liu JL, Liu JS, Liu JY, Liu MY, Liu RY, Liu SM, Liu W, Liu YN, Liu ZX, Long WJ, Lu R, Lv HK, Ma BQ, Ma LL, Ma XH, Mao JR, Masood A, Mitthumsiri W, Montaruli T, Nan YC, Pang BY, Pattarakijwanich P, Pei ZY, Qi MY, Ruffolo D, Rulev V, Sáiz A, Shao L, Shchegolev O, Sheng XD, Shi JR, Song HC, Stenkin YV, Stepanov V, Sun QN, Sun XN, Sun ZB, Tam PHT, Tang ZB, Tian WW, Wang BD, Wang C, Wang H, Wang HG, Wang JC, Wang JS, Wang LP, Wang LY, Wang RN, Wang W, Wang W, Wang XG, Wang XJ, Wang XY, Wang YD, Wang YJ, Wang YP, Wang Z, Wang Z, Wang ZH, Wang ZX, Wei DM, Wei JJ, Wei YJ, Wen T, Wu CY, Wu HR, Wu S, Wu WX, Wu XF, Xi SQ, Xia J, Xia JJ, Xiang GM, Xiao G, Xiao HB, Xin GG, Xin YL, Xing Y, Xu DL, Xu RX, Xue L, Yan DH, Yang CW, Yang FF, Yang JY, Yang LL, Yang MJ, Yang RZ, Yang SB, Yao YH, Yao ZG, Ye YM, Yin LQ, Yin N, You XH, You ZY, Yu YH, Yuan Q, Zeng HD, Zeng TX, Zeng W, Zeng ZK, Zha M, Zhai XX, Zhang BB, Zhang HM, Zhang HY, Zhang JL, Zhang JW, Zhang L, Zhang L, Zhang LX, Zhang PF, Zhang PP, Zhang R, Zhang SR, Zhang SS, Zhang X, Zhang XP, Zhang Y, Zhang Y, Zhang YF, Zhang YL, Zhao B, Zhao J, Zhao L, Zhao LZ, Zhao SP, Zheng F, Zheng Y, Zhou B, Zhou H, Zhou JN, Zhou P, Zhou R, Zhou XX, Zhu CG, Zhu FR, Zhu H, Zhu KJ, Zuo X, Huang XY. Extended Very-High-Energy Gamma-Ray Emission Surrounding PSR J0622+3749 Observed by LHAASO-KM2A. PHYSICAL REVIEW LETTERS 2021; 126:241103. [PMID: 34213924 DOI: 10.1103/physrevlett.126.241103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 03/23/2021] [Accepted: 05/10/2021] [Indexed: 06/13/2023]
Abstract
We report the discovery of an extended very-high-energy (VHE) gamma-ray source around the location of the middle-aged (207.8 kyr) pulsar PSR J0622+3749 with the Large High-Altitude Air Shower Observatory (LHAASO). The source is detected with a significance of 8.2σ for E>25 TeV assuming a Gaussian template. The best-fit location is (right ascension, declination) =(95.47°±0.11°,37.92°±0.09°), and the extension is 0.40°±0.07°. The energy spectrum can be described by a power-law spectrum with an index of -2.92±0.17_{stat}±0.02_{sys}. No clear extended multiwavelength counterpart of the LHAASO source has been found from the radio to sub-TeV bands. The LHAASO observations are consistent with the scenario that VHE electrons escaped from the pulsar, diffused in the interstellar medium, and scattered the interstellar radiation field. If interpreted as the pulsar halo scenario, the diffusion coefficient, inferred for electrons with median energies of ∼160 TeV, is consistent with those obtained from the extended halos around Geminga and Monogem and much smaller than that derived from cosmic ray secondaries. The LHAASO discovery of this source thus likely enriches the class of so-called pulsar halos and confirms that high-energy particles generally diffuse very slowly in the disturbed medium around pulsars.
Collapse
|
140
|
Wang S, Du J, Xi D, Shao F, Qiu M, Shao X, Liang Y, Liu B, Jin X, Fang J, Fang J. Role of GABAAR in the Transition From Acute to Chronic Pain and the Analgesic Effect of Electroacupuncture on Hyperalgesic Priming Model Rats. Front Neurosci 2021; 15:691455. [PMID: 34220444 PMCID: PMC8248374 DOI: 10.3389/fnins.2021.691455] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 05/25/2021] [Indexed: 11/18/2022] Open
Abstract
Chronic pain is a costly health problem that impairs health-related quality of life when not effectively treated. Regulating the transition from acute to chronic pain is a new therapeutic strategy for chronic pain that presents a major clinical challenge. The underlying mechanisms of pain transition are not entirely understood, and strategies for preventing this transition are lacking. Here, a hyperalgesic priming model was used to study the potential mechanism by which γ-aminobutyric acid receptor type A (GABAAR) in the dorsal root ganglion (DRG) contributes to pain transition. Furthermore, electroacupuncture (EA), a modern method of acupuncture, was administered to regulate pain transition, and the mechanism underlying EA’s regulatory effect was investigated. Hyperalgesic priming was induced by intraplanar injection of carrageenan (Car)/prostaglandin E2 (PGE2). The decrease in mechanical withdrawal threshold (MWT) induced by PGE2 returned to baseline 4 h after injection in NS + PGE2 group, and still persisted 24 h after injection in Car + PGE2 group. Lower expression of GABAAR in the lumbar DRG was observed in the model rats. Furthermore, activating or blocking GABAAR could reversed the long-lasting hyperalgesia induced by Car/PGE2 injection or produced a persistent hyperalgesia. In addition, GABAAR may be involved in Protein Kinase C epsilon (PKCε) activation in the DRG, a mark molecular of pain transition. EA considerably increased the mechanical pain thresholds of hyperalgesic priming model mammals in both the acute and chronic phases. Furthermore, EA upregulated the expression of GABAAR and inhibited the activation of PKCε in the DRG. In addition, peripheral administration of picrotoxin blocked the analgesic effect of EA on the model rats and abolished the regulatory effect of EA on PKCε activation. These findings suggested that GABAAR plays a key role in both the transition from acute to chronic pain and the analgesic effect of EA on hyperalgesic priming.
Collapse
|
141
|
Kiltz U, Sfikakis P, Gullick N, Theodoridou A, Brandt-Juergens J, Lespessailles E, Rashkov R, Fang J, Pournara E, Schulz B, Jagiello P, Gaffney K. POS0234 SECUKINUMAB RETENTION AND SAFETY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: 2 YEAR INTERIM RESULTS OF THE OBSERVATIONAL SERENA STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2263] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:SERENA is an ongoing, prospective, non-interventional study evaluating retention, effectiveness, safety/tolerability and quality of life in more than 2900 patients (pts) with moderate to severe plaque psoriasis, active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS) treated with secukinumab (SEC) at 438 sites across Europe for a period of up to 5 years1.Objectives:We present interim results reporting SEC treatment retention and safety data through 2 years in the PsA and AS pts enrolled in the study.Methods:This interim analysis presents data from 534 PsA and 470 AS pts who were enrolled (target population fulfilling all eligibility criteria) in the study and were followed up for at least 2 years. Pts (aged ≥18 years) with active PsA or AS should have received at least 16 weeks SEC treatment before enrolment in the study1. Retention rate was defined as the percentage of pts who have not discontinued SEC treatment. A treatment break was defined as interruption of therapy for at least 3 months after last injection.Results:The mean treatment duration prior to enrolment in the study was 1.0 year and 0.91 year for PsA and AS, respectively. The retention rates for SEC after 1 year since enrolment and since initiation of treatment were: PsA, 85.2% [n=519, CI: 82.01–88.32] and 96.8% [n=528, CI: 95.18–98.38]; AS, 85.8% [n=452, CI: 82.52–89.17] and 94.2% [n=464, CI: 91.94–96.42], respectively. After 2 years since enrolment and since initiation of treatment, the retention rates were: PsA, 74.9% [n=498, CI: 70.99–78.81] and 87.0% [n=515, CI: 83.99–89.99]; AS, 78.9% [n=437, CI: 75.01–82.88] and 84.8% [n=454, CI: 81.39–88.21], respectively. Survival probabilities for individual indications are presented in Figure 1. At baseline, the majority of PsA (79.5%; n/N=423/532) pts were receiving SEC 300 mg, while 97.0% (n/N=456/470) of AS pts were receiving SEC 150 mg. The majority of pts continued their initial SEC dose; “no dose change” in SEC treatment was reported after 1 and 2 years in the study (Year 1: PsA, 93.4% [n=499] and AS, 92.6% [n=435]; Year 2: PsA, 89.7% [n=479] and AS, 87.9% [n=413]). SEC treatment break was recorded for 31 PsA pts [median (min, max) treatment break duration in days: 125.0 (61, 461)] and for 42 AS [118.0 (61, 813)] pts mainly due to adverse events reported in 58.1% (n=18) and 45.2% (n=19) of pts, respectively. The retreatment started with monthly dosing in most of the cases: PsA, 80.6% (n/N=25/31) and AS, 76.2% (n/N=32/42). No new or unexpected safety signals were reported (Table 1).Table 1.Safety profile of treatment-emergent adverse events within the study periodAE summary, n (%)PsA N=575AS N=499Year 1Year 2Year 1Year 2Subject with any AE239 (41.6)289 (50.3)203 (40.7)247 (49.5)Subject with any serious AE29 (5.0)45 (7.8)29 (5.8)44 (8.8)Subject with AE leading to discontinuation55 (9.6)84 (14.6)47 (9.4)62 (12.4)Death0 (0.0)0 (0.0)0 (0.0)1 (0.2)AEs of special interest, n (IR per 100 subject-years)Serious infections and infestations5 (0.96)9 (0.95)8 (1.78)11 (1.33)Candida infections1 (0.19)2 (0.21)2 (0.44)2 (0.24)Malignancy5 (0.96)7 (0.74)N/R3 (0.36)Major adverse cardiovascular eventsN/R1 (0.11)2 (0.44)3 (0.36)Inflammatory bowel diseaseN/RN/R1 (0.22)1 (0.12)N, total number of patients in the safety set; n, number of patients with event; AE, adverse events; IR, incidence rate; N/R, not reported.Conclusion:Secukinumab retention rates in a real world setting after more than 2 years since initiation of treatment and after 2 years since enrolment in the study indicate high persistence rates. Safety data collected prospectively for up to 2 years confirm the favorable safety profile of secukinumab.References:[1]Kiltz, U et al. Adv Ther 2020; 37:2865–83.Disclosure of Interests:Uta Kiltz Consultant of: AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Grünenthal, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Grünenthal, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Petros Sfikakis Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli-Lilly, Janssen, Novartis and Pfizer, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli-Lilly, Janssen, Novartis and Pfizer, Nicola Gullick Speakers bureau: AbbVie, Celgene, Eli Lilly, Izana, Janssen, Novartis, UCB., Consultant of: AbbVie, Celgene, Eli Lilly, Izana, Janssen, Novartis, UCB., Grant/research support from: AbbVie, Celgene, Eli Lilly, Izana, Janssen, Novartis, UCB., Athina Theodoridou Consultant of: UCB, Amgen, Novartis, Jan Brandt-Juergens Speakers bureau: AbbVie, Pfizer, Roche, Sanofi-Aventis, Novartis, Lilly, MSD, UCB, BMS, Janssen, and Medac, Consultant of: AbbVie, Pfizer, Roche, Sanofi-Aventis, Novartis, Lilly, MSD, UCB, BMS, Janssen, and Medac, Eric Lespessailles Speakers bureau: Amgen, Expanscience, Lilly and MSD, Consultant of: Amgen, Expanscience, Lilly and MSD, Grant/research support from: Abbvie, Amgen, Lilly, MSD and UCB, Rasho Rashkov Speakers bureau: AbbVie, Amgen, Pfizer, Novartis, MSD, UCB, Roche and Janssen, Consultant of: AbbVie, Amgen, Pfizer, Novartis, MSD, UCB, Roche and Janssen, Jenny Fang Employee of: Novartis, Effie Pournara Shareholder of: Novartis, Employee of: Novartis, Barbara Schulz Employee of: Novartis, Piotr Jagiello Employee of: Novartis, Karl Gaffney Speakers bureau: AbbVie, Celgene, Lilly, Pfizer, Gilead, MSD, Novartis and UCB, Consultant of: AbbVie, Celgene, Lilly, Pfizer, Gilead, MSD, Novartis and UCB, Grant/research support from: AbbVie, Celgene, Lilly, Pfizer, Gilead, MSD, Novartis and UCB.
Collapse
|
142
|
Cao Z, Aharonian FA, An Q, Axikegu, Bai LX, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Cai H, Cai JT, Cao Z, Chang J, Chang JF, Chang XC, Chen BM, Chen J, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen SH, Chen SZ, Chen TL, Chen XL, Chen Y, Cheng N, Cheng YD, Cui SW, Cui XH, Cui YD, Dai BZ, Dai HL, Dai ZG, Danzengluobu, Della Volpe D, D Ettorre Piazzoli B, Dong XJ, Fan JH, Fan YZ, Fan ZX, Fang J, Fang K, Feng CF, Feng L, Feng SH, Feng YL, Gao B, Gao CD, Gao Q, Gao W, Ge MM, Geng LS, Gong GH, Gou QB, Gu MH, Guo JG, Guo XL, Guo YQ, Guo YY, Han YA, He HH, He HN, He JC, He SL, He XB, He Y, Heller M, Hor YK, Hou C, Hou X, Hu HB, Hu S, Hu SC, Hu XJ, Huang DH, Huang QL, Huang WH, Huang XT, Huang ZC, Ji F, Ji XL, Jia HY, Jiang K, Jiang ZJ, Jin C, Kuleshov D, Levochkin K, Li BB, Li C, Li C, Li F, Li HB, Li HC, Li HY, Li J, Li K, Li WL, Li X, Li X, Li XR, Li Y, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu H, Liu HD, Liu J, Liu JL, Liu JS, Liu JY, Liu MY, Liu RY, Liu SM, Liu W, Liu YN, Liu ZX, Long WJ, Lu R, Lv HK, Ma BQ, Ma LL, Ma XH, Mao JR, Masood A, Mitthumsiri W, Montaruli T, Nan YC, Pang BY, Pattarakijwanich P, Pei ZY, Qi MY, Ruffolo D, Rulev V, Sáiz A, Shao L, Shchegolev O, Sheng XD, Shi JR, Song HC, Stenkin YV, Stepanov V, Sun QN, Sun XN, Sun ZB, Tam PHT, Tang ZB, Tian WW, Wang BD, Wang C, Wang H, Wang HG, Wang JC, Wang JS, Wang LP, Wang LY, Wang RN, Wang W, Wang W, Wang XG, Wang XJ, Wang XY, Wang YD, Wang YJ, Wang YP, Wang Z, Wang Z, Wang ZH, Wang ZX, Wei DM, Wei JJ, Wei YJ, Wen T, Wu CY, Wu HR, Wu S, Wu WX, Wu XF, Xi SQ, Xia J, Xia JJ, Xiang GM, Xiao G, Xiao HB, Xin GG, Xin YL, Xing Y, Xu DL, Xu RX, Xue L, Yan DH, Yang CW, Yang FF, Yang JY, Yang LL, Yang MJ, Yang RZ, Yang SB, Yao YH, Yao ZG, Ye YM, Yin LQ, Yin N, You XH, You ZY, Yu YH, Yuan Q, Zeng HD, Zeng TX, Zeng W, Zeng ZK, Zha M, Zhai XX, Zhang BB, Zhang HM, Zhang HY, Zhang JL, Zhang JW, Zhang L, Zhang L, Zhang LX, Zhang PF, Zhang PP, Zhang R, Zhang SR, Zhang SS, Zhang X, Zhang XP, Zhang Y, Zhang Y, Zhang YF, Zhang YL, Zhao B, Zhao J, Zhao L, Zhao LZ, Zhao SP, Zheng F, Zheng Y, Zhou B, Zhou H, Zhou JN, Zhou P, Zhou R, Zhou XX, Zhu CG, Zhu FR, Zhu H, Zhu KJ, Zuo X. Ultrahigh-energy photons up to 1.4 petaelectronvolts from 12 γ-ray Galactic sources. Nature 2021; 594:33-36. [PMID: 34002091 DOI: 10.1038/s41586-021-03498-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 03/26/2021] [Indexed: 02/04/2023]
Abstract
The extension of the cosmic-ray spectrum beyond 1 petaelectronvolt (PeV; 1015 electronvolts) indicates the existence of the so-called PeVatrons-cosmic-ray factories that accelerate particles to PeV energies. We need to locate and identify such objects to find the origin of Galactic cosmic rays1. The principal signature of both electron and proton PeVatrons is ultrahigh-energy (exceeding 100 TeV) γ radiation. Evidence of the presence of a proton PeVatron has been found in the Galactic Centre, according to the detection of a hard-spectrum radiation extending to 0.04 PeV (ref. 2). Although γ-rays with energies slightly higher than 0.1 PeV have been reported from a few objects in the Galactic plane3-6, unbiased identification and in-depth exploration of PeVatrons requires detection of γ-rays with energies well above 0.1 PeV. Here we report the detection of more than 530 photons at energies above 100 teraelectronvolts and up to 1.4 PeV from 12 ultrahigh-energy γ-ray sources with a statistical significance greater than seven standard deviations. Despite having several potential counterparts in their proximity, including pulsar wind nebulae, supernova remnants and star-forming regions, the PeVatrons responsible for the ultrahigh-energy γ-rays have not yet been firmly localized and identified (except for the Crab Nebula), leaving open the origin of these extreme accelerators.
Collapse
|
143
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu S, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, He K, Heinsius F, Heinz C, Held T, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Hüsken N, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Lin C, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu S, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lusso S, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Poling R, Prasad V, Qi H, Qi H, Qi K, Qi M, Qi T, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan D, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidenkaff P, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan X, Yuan Y, Yuan Z, Yue C, Zafar A, Zeng XZ, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Search for the decay
Ds+→a0(980)0e+νe. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.103.092004] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
144
|
Fan X, Fang J, Wu X, Poulsen K, Miyata T, Kim A, Yu L, Wang X, Zhang X, Zhang K, Han Q, Liu Z. Effect of HIV infection on pre- and post-liver transplant mortality in patients with organ failure. HIV Med 2021; 22:662-673. [PMID: 33964108 DOI: 10.1111/hiv.13113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/31/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Organ failure (OF), a leading cause of death in HIV-positive individuals, is common in patients undergoing liver transplantation (LT). We examined the impact of HIV infection on pre- and post-LT mortalities in cirrhotic patients stratified by the number and type of OFs. METHODS We performed a cross-sectional study and a retrospective cohort study using the US National Inpatient Sample (NIS) and the United Network for Organ Sharing (UNOS) registry data, respectively. Patients who had not yet undergone LT from the NIS database (2010-2014) and patients undergoing LT from the UNOS database (2003-2016) were included in the study. RESULTS Analysis of patients (201 348) from the NIS database showed that one [adjusted odds ratio (aOR) 1.531; 95% confidence interval (CI) 1.160-2.023], two (aOR 1.624; 95% CI 1.266-2.083) or three or more OFs (aOR 1.349; 95% CI 1.165-1.562) were associated with higher pre-LT mortality in HIV-infected patients compared with HIV-negative patients with the corresponding number of OFs. In patients without OF, HIV infection was not associated with increased pre-LT mortality. UNOS data for patients undergoing LT (38 942) showed that the presence of two or more OFs was associated with increased post-LT 1-year mortality in HIV-infected patients compared with non-HIV-infected patients with the corresponding number of OFs (aOR 2.342; 95% CI 1.576-3.480). However, in patients with no OF or only one OF, HIV infection was not associated with increased post-LT 1-year mortality (aOR 1.372; 95% CI 0.911-2.068). CONCLUSIONS The results of this study emphasize the importance of preventing OF development, and justify LT for HIV-infected patients with no or only one OF.
Collapse
|
145
|
Wang W, Zhou Y, Cai Y, Wang S, Shao F, Du J, Fang J, Liu J, Shao X, Liu B, Fang J, Liang Y. Phosphoproteomic Profiling of Rat's Dorsal Root Ganglia Reveals mTOR as a Potential Target in Bone Cancer Pain and Electro-Acupuncture's Analgesia. Front Pharmacol 2021; 12:593043. [PMID: 33995007 PMCID: PMC8117331 DOI: 10.3389/fphar.2021.593043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 04/08/2021] [Indexed: 01/18/2023] Open
Abstract
Bone cancer pain (BCP) is a clinical refractory mixed pain involving neuropathic and inflammatory pain, with the underlying mechanisms remaining largely unknown. Electro-acupuncture (EA) can partly alleviate BCP according to previous research. We aim to explore the proteins and major pathways involved in BCP and EA treatment through phosphoproteomic profiling. BCP rat model was built by tibial inoculation of MRMT-1 mammary gland carcinoma cells. Mechanical hyperalgesia determined by paw withdrawal thresholds (PWTs) and bone destruction manifested on the radiographs confirmed the success of modeling, which were attenuated by EA treatment. The differentially expressed phosphorylated proteins (DEPs) co-regulated by BCP modeling and EA treatment in rat dorsal root ganglions (DRGs) were analyzed through PEX100 Protein microarray. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that DEPs were significantly enriched in mammalian target of rapamycin (mTOR) signaling pathway. The phosphorylations of mTOR at Ser2448 and Thr2446 were increased in BCP and downregulated by EA. In addition, the phosphorylation of S6K and Akt, markers of the mTOR complex, were also increased in BCP and downregulated by EA. Inhibition of mTOR signaling alleviated the PWTs of BCP rats, while the mTOR agonist impaired the analgesic effect of EA. Thus, our study provided a landscape of protein phosphorylation changes in DRGs of EA-treated BCP rats and revealed that mTOR signaling can be potentially targeted to alleviate BCP by EA treatment.
Collapse
|
146
|
Yu J, Du J, Fang J, Liu Y, Xiang X, Liang Y, Shao X, Fang J. The interaction between P2X3 and TRPV1 in the dorsal root ganglia of adult rats with different pathological pains. Mol Pain 2021; 17:17448069211011315. [PMID: 33906494 PMCID: PMC8108079 DOI: 10.1177/17448069211011315] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Peripheral inflammatory and neuropathic pain are closely related to the activation of purinergic receptor P2X ligand-gated ion channel 3 (P2X3) and transient receptor potential vanilloid 1 (TRPV1), but the interaction between P2X3 and TRPV1 in different types of pathological pain has rarely been reported. In this study, complete Freund’s adjuvant (CFA)-induced inflammatory pain and spared nerve injury (SNI)-induced neuropathic pain models were established in adult rats. The interactions between P2X3 and TRPV1 in the dorsal root ganglion were observed by pharmacological, co-immunoprecipitation, immunofluorescence and whole-cell patch-clamp recording assays. TRPV1 was shown to promote the induction of spontaneous pain caused by P2X3 in the SNI model, but the induction of spontaneous pain behaviour by TRPV1 was not completely dependent on P2X3 in vivo. In both the CFA and SNI models, the activation of peripheral P2X3 enhanced the effect of TRPV1 on spontaneous pain, while the inhibition of peripheral TRPV1 reduced the induction of spontaneous pain by P2X3 in the CFA model. TRPV1 and P2X3 had inhibitory effects on each other in the inflammatory pain model. During neuropathic pain, P2X3 facilitated the function of TRPV1, while TRPV1 had an inhibitory effect on P2X3. These results suggest that the mutual effects of P2X3 and TRPV1 differ in cases of inflammatory and neuropathic pain in rats.
Collapse
|
147
|
Fang J, Sun Y, Sun XL, Wang HC, Lyu HX, Zhou YM. [Application of navigation system for dental implant in crossing-over the inferior alveolar nerve: a case report]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2021; 56:377-379. [PMID: 33832041 DOI: 10.3760/cma.j.cn112144-20201222-00629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
148
|
Yin M, Ishihara S, Anderson T, Stehlik J, McKellar S, Dranow E, Gilbert E, Selzman C, Fang J, Drakos S, Wever-Pinzon O. Improving Prediction of Acute Right Ventricular Failure in Patients Undergoing Left Ventricular Assist Devices Using Novel Comprehensive Eighteen-Segment Echocardiographic Strain Analysis. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
149
|
Fang J, Chen YL, Yao HB, Peng SS, Yang P, Ding ZY. MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 24:2335-2346. [PMID: 32196585 DOI: 10.26355/eurrev_202003_20500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE This study was aimed to investigate the expression characteristics of MIIP in hepatocellular carcinoma (HCC), and to further explore whether it can inhibit the malignant progression of this disease via regulating AKT expression. PATIENTS AND METHODS Real-time quantitative PCR (qRT-PCR) was performed to examine the expression of MIIP in tumor and paracancerous tissue specimens of 39 patients with HCC, and to analyze the interplay between MIIP expression and clinical indicators and prognosis of HCC patients. At the same time, in HCC cell lines, the expression of MIIP was further verified using qRT-PCR. In addition, MIIP overexpression and knockdown models were constructed using lentivirus in HCC cell lines (Bel-7402 and Hep3B), and the influence of MIIP on the biological function of HCC cells was analyzed through CCK-8 and transwell migration assays. Finally, luciferase reporting assay and cell reverse experiments were applied to further explore the potential molecular mechanism and the interaction between MIIP and AKT. RESULTS The results of qRT-PCR showed that the expression level of MIIP in HCC tissue samples was remarkably lower than that in adjacent ones, with a statistically significant difference. Compared with patients with high expression of MIIP, patients with low MIIP expression had a higher occurrence of distant metastasis and a lower overall survival rate. Similarly, compared with control group, the proliferation and migration ability of HCC cells in MIIP knockdown group (sh-MIIP) was remarkably enhanced, while the opposite result was observed in MIIP overexpression group. In addition, qRT-PCR results also revealed that AKT and MIIP were negatively correlated in HCC tissues. At the same time, the results of luciferase reporter gene assay demonstrated that MIIP can be targeted by AKT through certain binding site. Additionally, cell reverse experiment found that there might exist a mutual regulation between MIIP and AKT, thereby jointly regulating the malignant progression of HCC. CONCLUSIONS MIIP expression is remarkably decreased both in HCC tissues and cell lines; meanwhile, the low expression of MIIP is positively correlated with the occurrence of distant metastasis and poor prognosis of patients with HCC. In addition, MIIP may be able to inhibit the malignant progression of HCC by modulating AKT expression.
Collapse
|
150
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai XC, Dbeyssi A, de Boer RB, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Fu Y, Gao Y, Gao Y, Gao Y, Gao YG, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guo YP, Guskov A, Han TT, Hao XQ, Harris FA, He KL, Heinsius FH, Heinz CH, Held T, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Huesken N, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Jiang HB, Jiang XS, Jiang XY, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li JL, Li JQ, Li K, Li LK, Li L, Li PL, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li ZY, Liang H, Liang H, Liang YF, Liang YT, Liao LZ, Libby J, Lin CX, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XN, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Mo YJ, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Pitka A, Poling R, Prasad V, Qi H, Qi HR, Qi KH, Qi M, Qi TY, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin LQ, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shao M, Shen CP, Shen PX, Shen XY, Shi BA, Shi HC, Shi RS, Shi X, Shi XD, Song WM, Song YX, Sosio S, Spataro S, Su KX, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Uman I, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang Y, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidenkaff P, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao YJ, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu JJ, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang RX, Yang SL, Yang SL, Yang YH, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan W, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Yuncu A, Zafar AA, Zeng Y, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XY, Zhang Y, Zhang YH, Zhang YT, Zhang Y, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng Y, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu XL, Zhu YC, Zhu ZA, Zou BS, Zou JH. Observation of a Near-Threshold Structure in the K^{+} Recoil-Mass Spectra in e^{+}e^{-}→K^{+}(D_{s}^{-}D^{*0}+D_{s}^{*-}D^{0}). PHYSICAL REVIEW LETTERS 2021; 126:102001. [PMID: 33784133 DOI: 10.1103/physrevlett.126.102001] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 02/05/2021] [Indexed: 06/12/2023]
Abstract
We report a study of the processes of e^{+}e^{-}→K^{+}D_{s}^{-}D^{*0} and K^{+}D_{s}^{*-}D^{0} based on e^{+}e^{-} annihilation samples collected with the BESIII detector operating at BEPCII at five center-of-mass energies ranging from 4.628 to 4.698 GeV with a total integrated luminosity of 3.7 fb^{-1}. An excess of events over the known contributions of the conventional charmed mesons is observed near the D_{s}^{-}D^{*0} and D_{s}^{*-}D^{0} mass thresholds in the K^{+} recoil-mass spectrum for events collected at sqrt[s]=4.681 GeV. The structure matches a mass-dependent-width Breit-Wigner line shape, whose pole mass and width are determined as (3982.5_{-2.6}^{+1.8}±2.1) MeV/c^{2} and (12.8_{-4.4}^{+5.3}±3.0) MeV, respectively. The first uncertainties are statistical and the second are systematic. The significance of the resonance hypothesis is estimated to be 5.3 σ over the contributions only from the conventional charmed mesons. This is the first candidate for a charged hidden-charm tetraquark with strangeness, decaying into D_{s}^{-}D^{*0} and D_{s}^{*-}D^{0}. However, the properties of the excess need further exploration with more statistics.
Collapse
|